MARKET

PFNX

PFNX

PFENEX
AMEX

Real-time Quotes | Nasdaq Last Sale

10.73
+0.24
+2.29%
After Hours: 10.73 0 0.00% 16:00 12/11 EST
OPEN
10.52
PREV CLOSE
10.49
HIGH
10.80
LOW
10.41
VOLUME
273.44K
TURNOVER
--
52 WEEK HIGH
11.39
52 WEEK LOW
3.130
MARKET CAP
339.88M
P/E (TTM)
-22.3542
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of PFNX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

PFNX News

  • Pfenex to Present at the Piper Jaffray 31st Annual Healthcare Conference
  • GlobeNewswire.11/20 21:10
  • Pfenex to Present at the Evercore ISI HealthCONx Conference 2019
  • GlobeNewswire.11/19 21:10
  • Edited Transcript of PFNX earnings conference call or presentation 7-Nov-19 9:30pm GMT
  • Thomson Reuters StreetEvents.11/19 02:20
  • The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing
  • Benzinga.11/14 13:07

More

Industry

Biotechnology & Medical Research
-0.34%
Pharmaceuticals & Medical Research
+0.06%

Hot Stocks

Name
Price
%Change

About PFNX

Pfenex Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of biosimilar and therapeutic equivalent products to branded therapeutics and other high-value and difficult-to-manufacture proteins. Its lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab). Its next advanced product candidates are PF530 and PF708. PF530 is a biosimilar candidate to Betaseron (interferon beta-1b). PF708 is being developed as a therapeutically equivalent peptide to Forteo (teriparatide), which is for the treatment of osteoporosis. In addition to its three advanced product candidates, its pipeline includes over four other biosimilar candidates, as well as vaccines and next generation biologic candidates. Its product candidates are enabled by its protein production platform, Pfenex Expression Technology. It is also developing Px563L, an anthrax vaccine candidate, and Px533 as a prophylactic vaccine candidate against malaria infection.
More

Webull offers Pfenex Inc (PFNX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.